Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,866.24 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Benjamin Machinas Beneski sold 5,488 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $1.98, for a total transaction of $10,866.24. Following the completion of the transaction, the senior vice president now owns 218,507 shares of the company’s stock, valued at approximately $432,643.86. The trade was a 2.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Allogene Therapeutics Stock Performance

ALLO stock opened at $1.69 on Wednesday. The stock has a market cap of $354.35 million, a P/E ratio of -1.08 and a beta of 1.02. The firm has a 50 day simple moving average of $1.92 and a 200 day simple moving average of $2.30. Allogene Therapeutics, Inc. has a 52 week low of $1.32 and a 52 week high of $4.63.

Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on ALLO. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Institutional Trading of Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ALLO. Cibc World Markets Corp acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $26,000. PAX Financial Group LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $27,000. RPO LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $31,000. Caption Management LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $32,000. Finally, Syon Capital LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $39,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).